Macular telangiectasia – Diagnostics – Overview of Information and Clinical Research

Macular telangiectasia is a rare condition affecting the central part of the retina, the macula, causing gradual changes in vision. Understanding how this disease is detected and diagnosed is essential for anyone experiencing unexplained changes in their central sight, especially during their middle years.

Introduction: When to Seek Diagnostic Testing

If you notice that reading has become more difficult, straight lines appear wavy, or parts of words seem to disappear when you look directly at them, it may be time to see an eye specialist. These symptoms could indicate a problem with your macula, the part of your eye responsible for sharp central vision. Macular telangiectasia, often called MacTel, typically starts affecting people in their 40s and 50s, though changes may have been developing silently for years before becoming noticeable.^[1]

People who should consider diagnostic testing include those experiencing unexplained blurry vision, difficulty seeing in dim lighting, or small blind spots in their central vision that interfere with daily activities like driving or recognizing faces. Because MacTel is relatively rare and can be mistaken for more common conditions like age-related macular degeneration (a condition causing vision loss in older adults) or diabetic retinopathy, obtaining an accurate diagnosis is crucial.^[2]

Early detection matters because MacTel is a progressive disease, meaning it worsens over time. While the condition typically advances slowly over 10 to 20 years, monitoring its progression helps doctors watch for complications that could cause rapid vision loss. Additionally, misdiagnosis can lead to unnecessary treatments aimed at conditions you don’t actually have, while the real problem continues to develop.^[4]

⚠️ Important

If you experience a sudden loss of vision rather than gradual changes, contact your doctor immediately. This could signal complications like subretinal neovascularization, where abnormal new blood vessels form and leak, requiring prompt treatment to prevent permanent vision damage.

Diagnostic Methods for Identifying MacTel

Diagnosing macular telangiectasia requires a combination of clinical examination and specialized imaging tests. Because the early signs can be subtle and the condition is uncommon, doctors rely on multiple diagnostic tools to confirm the presence of MacTel and distinguish it from other macular diseases.^[4]

Clinical Eye Examination

The diagnostic process typically begins with a comprehensive eye examination. Your eye doctor will check your visual acuity, which measures how well you can see at various distances. During the examination of your retina, the doctor may notice characteristic signs of MacTel, including a grayish appearance of the retina near the fovea (the very center of the macula), loss of the normal reflective quality of the foveal surface, or small deposits that look like crystals.^[8]

The doctor may also observe abnormal blood vessels that appear twisted or enlarged near the fovea, or pigment changes where dark spots have formed in the retina. Sometimes tiny blood vessels meet at right angles, creating a distinctive pattern that helps identify MacTel. However, in early stages, these changes can be so subtle that they’re difficult to detect with examination alone.^[4]

Optical Coherence Tomography (OCT)

Optical coherence tomography, or OCT, has become one of the most important tools for diagnosing MacTel. This non-invasive imaging test uses light waves to take detailed cross-sectional pictures of your retina, much like an ultrasound uses sound waves. The machine doesn’t touch your eye and the test is painless.^[4]

OCT reveals hallmark features of MacTel that might not be visible during a regular examination. One nearly diagnostic finding is the presence of small cavity-like spaces in the retina near the fovea. These spaces appear as dark, empty areas on the scan and likely represent regions where supporting cells called Müller cells (specialized cells that help maintain retinal structure) and light-sensing cells have died off. Doctors can also see breaks or disruptions in the ellipsoid zone, which is a layer of the retina that appears as a bright line on OCT scans.^[8]

The OCT images help doctors measure the extent of photoreceptor loss and monitor how the disease progresses over time. This technology has made diagnosis much more accurate than in the past, when doctors relied solely on what they could see during examination.^[4]

Fluorescein Angiography

Fluorescein angiography is an imaging test that provides detailed information about the blood vessels in your retina. During this procedure, a special dye called fluorescein is injected into a vein in your arm. As the dye travels through your bloodstream and reaches the blood vessels in your eyes, a camera takes rapid-sequence photographs.^[8]

This test reveals the characteristic pattern of abnormal blood vessels in MacTel. The dye shows areas where small blood vessels have become widened and dilated, creating the telangiectasia that gives the disease its name. As the test progresses, areas of late leakage become visible, showing where fluid is seeping out of weakened blood vessels. The leakage typically appears in a pattern surrounding the fovea, particularly on the temporal (outer) side.^[8]

Fluorescein angiography is particularly useful for detecting complications. If abnormal new blood vessels have formed under or within the retina, a condition called subretinal neovascularization, the angiogram will show this clearly through distinctive leakage patterns. This information is crucial because these neovascular complications are responsible for much of the severe vision loss in advanced MacTel.^[4]

Fundus Autofluorescence

Fundus autofluorescence is a specialized imaging technique that detects natural fluorescence from substances in the retina, particularly in the retinal pigment epithelium layer beneath the photoreceptors. This test doesn’t require any injections—it simply uses special camera filters to capture the natural glow of certain molecules in your retina.^[8]

In people with MacTel, fundus autofluorescence typically shows increased brightness in the foveal region, indicating changes in the retinal pigment epithelium. Areas of decreased brightness, called hypoautofluorescence, often correspond to spots where pigment has accumulated or migrated into the retina. These patterns help doctors assess the extent and stage of the disease.^[8]

Additional Diagnostic Tests

Depending on your symptoms and examination findings, your doctor might order additional tests. Visual field testing can map out any blind spots or areas of reduced vision. Reading speed tests measure how quickly you can read text of different sizes, which provides objective information about how MacTel affects your functional vision.^[4]

Microperimetry is a specialized test that measures retinal sensitivity at different points across your macula. This test shows which areas of your retina are still working well and which have lost function. It can be particularly helpful for monitoring disease progression and evaluating treatment effects.^[9]

⚠️ Important

MacTel is often misdiagnosed as age-related macular degeneration or diabetic retinopathy because these conditions are more common and can cause similar symptoms. If you’ve been diagnosed with one of these conditions but your symptoms or test results don’t quite fit the pattern, ask your doctor whether MacTel could be a possibility. Getting the correct diagnosis ensures you receive appropriate monitoring and treatment.

Distinguishing MacTel from Other Conditions

One of the challenges in diagnosing MacTel is distinguishing it from other macular diseases. Unlike age-related macular degeneration, MacTel typically affects both eyes relatively equally and occurs in younger patients. The characteristic cavitary spaces seen on OCT and the specific pattern of vascular changes on fluorescein angiography help differentiate MacTel from other conditions.^[2]

MacTel also differs from diabetic maculopathy because it occurs in people without diabetes, or in diabetic patients but with different patterns of vascular changes. The gray appearance of the retina and the location of abnormalities right next to the fovea are distinctive features that help experienced retinal specialists recognize MacTel.^[4]

Diagnostics for Clinical Trial Qualification

Clinical trials investigating new treatments for MacTel use specific diagnostic criteria to determine which patients are eligible to participate. Understanding these criteria is important if you’re considering enrolling in research studies that might offer access to experimental therapies.^[2]

OCT-Based Anatomic Endpoints

Modern clinical trials for MacTel rely heavily on optical coherence tomography measurements to assess patient eligibility and monitor treatment effects. The primary measurement used is the ellipsoid zone area, which quantifies how much of the light-sensing photoreceptor layer remains intact. Clinical trials typically measure how fast this area is shrinking as the disease progresses.^[9]

To qualify for many MacTel trials, patients must have measurable areas of ellipsoid zone loss but still retain enough functioning retina that a treatment could potentially make a meaningful difference. The OCT must clearly show the characteristic cavitary changes and disruptions typical of MacTel type 2.^[10]

Visual Function Testing

Clinical trials also assess visual function through several standardized tests. Visual acuity measurements follow strict protocols, typically using standardized eye charts under controlled lighting conditions. Many trials require that participants have a certain level of remaining vision—enough to potentially benefit from treatment but showing evidence of disease progression.^[4]

Reading speed testing has become particularly important in MacTel trials. Researchers measure how many words per minute you can read using standardized text formats. This functional measure reflects how MacTel affects daily life activities and provides an outcome that patients care about. Some trials track whether treatments can slow the decline in reading speed compared to untreated patients.^[9]

Retinal Sensitivity Measurements

Microperimetry, which tests how sensitive different parts of your retina are to light, is another important qualification tool for clinical trials. This test creates a detailed map showing which areas of your macula are functioning well and which have lost sensitivity. Trial eligibility often depends on having measurable but not complete loss of retinal sensitivity in the macular region.^[9]

Disease Stage Classification

Clinical trials often enroll patients at specific disease stages. Early-stage MacTel might show only subtle changes on OCT and minimal visual symptoms, while advanced stages demonstrate extensive photoreceptor loss, significant visual impairment, or complications like neovascularization. The classification system helps researchers study treatments that might work best at particular disease phases.^[4]

Exclusion of Other Conditions

To participate in MacTel clinical trials, diagnostic testing must confirm that your vision problems are specifically due to MacTel and not other eye diseases. This requires comprehensive evaluation including fluorescein angiography to document the characteristic vascular patterns and rule out other causes of macular disease. Patients with concurrent conditions that significantly affect vision, such as advanced cataracts or other retinal diseases, may not qualify for trials.^[9]

Bilateral Disease Documentation

Because MacTel type 2 is a bilateral disease affecting both eyes, clinical trials typically require diagnostic evidence of disease in both eyes, though the severity may differ between them. The diagnostic workup includes testing and imaging both eyes separately to document the extent of disease in each eye. Some trials may treat only one eye while using the other as a comparison, while other trials treat both eyes.^[4]

Registry Participation

The MacTel Project, a natural history study and patient registry coordinated through the Lowy Medical Research Institute, has enrolled patients at more than 60 centers worldwide. This registry collects detailed diagnostic information including clinical examination findings, multimodal imaging, and visual function testing. By enrolling in the registry, patients contribute to research advancing the understanding of MacTel and may gain opportunities to participate in clinical trials testing new treatments.^[2]

Registry participation typically requires comprehensive baseline diagnostic testing and periodic follow-up examinations to track disease progression. The standardized protocols used across registry sites ensure that data collected worldwide can be compared and combined, accelerating research progress.^[2]

Prognosis and Survival Rate

Prognosis

The prognosis for people with macular telangiectasia varies considerably depending on the stage of disease and whether complications develop. MacTel type 2 is a slowly progressive condition, with most patients experiencing a gradual decline in central vision over 10 to 20 years. Visual acuity typically decreases by about one letter on a Snellen eye chart each year, though this rate can vary between individuals.^[23]

Many people with MacTel maintain useful vision throughout their lives and can continue most daily activities, though reading and driving may become progressively more challenging. The disease affects the central macula, responsible for detailed vision, but typically spares peripheral vision, so MacTel rarely causes complete blindness.^[5]

The development of complications significantly affects prognosis. Subretinal neovascularization, where abnormal new blood vessels grow beneath the retina, occurs in some patients and can cause rapid vision loss. This complication, along with progressive atrophy of the photoreceptors and retinal pigment epithelium, is responsible for most severe vision impairment in advanced cases. However, when neovascularization is detected early and treated promptly with anti-VEGF injections, vision can often be stabilized or improved.^[4]

The bilateral nature of MacTel type 2 means both eyes are affected, though they may progress at different rates. Some patients find that one eye remains relatively functional while the other deteriorates more rapidly. This asymmetry can help maintain quality of life even as the disease progresses, as the better eye often compensates for losses in the more affected eye.^[2]

Factors that may influence prognosis include the age at diagnosis, the rate of photoreceptor loss, and the presence of other health conditions. Recent advances in understanding MacTel as a neurodegenerative disease rather than primarily a vascular problem have opened new avenues for treatments aimed at preserving retinal cells and slowing progression. The approval of new therapies using encapsulated cell technology to deliver protective factors to the retina represents a significant advancement that may improve future outcomes for patients diagnosed with MacTel.^[9]

Survival rate

Macular telangiectasia does not affect overall survival or life expectancy. It is an eye condition that impacts vision but does not pose any threat to general health or longevity. Patients with MacTel have the same life expectancy as the general population. The disease’s impact is limited to visual function and quality of life related to vision loss, but it does not cause systemic illness or reduce survival rates.^[5]

#1 Clinical Trials Search in Europe